Sorry, you need to enable JavaScript to visit this website.
  1. Home
  2. Our Science
  3. Clinical Trials
  4. Plain Language Study Results Summaries

Plain Language Study Results Summaries

What Are Plain Language Study Results Summaries?

Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries, also called plain language summaries, simple summaries, and trial results summaries, are intended to make clinical results understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.

Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials.

Filter Results

Refine your search results by using the dropdown filters below. Click “reset” to return to the full list of available studies.

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
Language: English
ViewDownloadPrint
Étude de phase 1b/2 portant sur LGX818 en association avec MEK162 chez des patients adultes atteints de tumeurs solides avancées présentant une mutation du gène BRAF
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
Language: French
ViewDownloadPrint
Eine Phase-Ib/II-Studie zu LGX818 in Kombination mit MEK162 bei erwachsenen Patienten mit fortgeschrittenen soliden Tumoren mit BRAF-Mutation
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
Language: German
ViewDownloadPrint
Studio di fase Ib/II su LGX818 in combinazione con MEK162 in pazienti adulti con tumori solidi avanzati dipendenti da BRAF
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
Language: Italian
ViewDownloadPrint
Estudio de fase 1b/2 de LGX818 en combinación con MEK162 en pacientes adultos con tumores sólidos avanzados dependientes de BRAF
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
Language: Spanish
ViewDownloadPrint
A Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Category & Conditions: Skin Diseases and Conditions
Study Phase : 2
Medicine: brepocitinib (PF-06700841)
Language: English
ViewDownloadPrint
A Study of PF-06700841 to Determine the Beneficial Effect at 16 Weeks and the Safety and Beneficial Effect up to 1 Year in Subjects with Active Psoriatic Arthritis
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 2
Medicine: brepocitinib (PF-06700841)
Language: English
ViewDownloadPrint
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
Category & Conditions: Skin Diseases and Conditions
Study Phase : 2
Medicine: brepocitinib (PF-06700841), ritlecitinib (PF-06651600)
Language: English
ViewDownloadPrint
Study to Compare How Two Different Doses of Danuglipron Affect the Level of Rosuvastatin and Midazolam in the Blood of Adult Participants With Obesity
Category & Conditions: Diabetes and Metabolic Disorders
Study Phase : 1
Medicine: danuglipron (PF-06882961)
Language: English
ViewDownloadPrint
Pharmacokinetic Study of PF-06882961 in Participants With Type 2 Diabetes Mellitus With Varying Degrees of Renal Impairment and in Participants Without Renal Impairment.
Category & Conditions: Diabetes and Metabolic Disorders
Study Phase : 1
Medicine: danuglipron (PF-06882961)
Language: English
ViewDownloadPrint
A Study on How Danuglipron Effects Blood Levels of Atorvastatin and Midazolam in Healthy Adults, and of Oral Contraceptives in Healthy Post-Menopausal Females
Category & Conditions: Diabetes and Metabolic Disorders
Study Phase : 1
Medicine: danuglipron (PF-06882961)
Language: English
ViewDownloadPrint